$ELTX
Elicio Therapeutics, Inc.

2023 Q3 Form 10-Q Financial Statement

#000160148523000052 Filed on August 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q2
Revenue $0.00 $0.00 $653.0K
YoY Change -100.0% 20.93%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.510M $2.830M $3.615M
YoY Change 5.88% -21.72% -16.71%
% of Gross Profit
Research & Development $7.264M $4.944M $6.073M
YoY Change 147.24% -18.59% -57.95%
% of Gross Profit
Depreciation & Amortization $0.00 $190.0K $31.00K
YoY Change -100.0% 512.9% 34.78%
% of Gross Profit
Operating Expenses $7.264M $4.944M $6.073M
YoY Change 147.24% -18.59% -57.95%
Operating Profit -$10.77M -$7.777M -$9.035M
YoY Change 19.02% -13.92% -50.48%
Interest Expense $1.000K $714.0K -$146.0K
YoY Change -98.11% -589.04% -317.91%
% of Operating Profit
Other Income/Expense, Net $113.0K $218.0K -$104.0K
YoY Change 82.26% -309.62% -108.87%
Pretax Income -$10.66M -$7.560M -$9.139M
YoY Change 18.6% -17.28% -46.47%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$10.66M -$7.559M -$9.139M
YoY Change 18.58% -17.29% -46.47%
Net Earnings / Revenue -1399.54%
Basic Earnings Per Share -$1.27 -$2.44 -$0.30
Diluted Earnings Per Share -$1.27 -$2.44 -$0.30
COMMON SHARES
Basic Shares Outstanding 8.388M shares 30.11M shares 29.97M shares
Diluted Shares Outstanding 8.376M shares 3.101M shares 29.97M shares

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $14.80M $21.70M $63.37M
YoY Change -73.16% -65.76% -45.98%
Cash & Equivalents $14.80M $21.70M $63.40M
Short-Term Investments
Other Short-Term Assets $5.000M $4.000M $463.0K
YoY Change 1433.74% 763.93% -13.94%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $19.93M $26.23M $65.89M
YoY Change -64.84% -60.2% -44.96%
LONG-TERM ASSETS
Property, Plant & Equipment $772.0K $919.0K $388.0K
YoY Change 153.95% 136.86% -5.83%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $865.0K
YoY Change 2.61%
Other Assets $3.500M $3.500M $86.00K
YoY Change 4566.67% 3969.77% 126.32%
Total Long-Term Assets $11.06M $11.39M $4.928M
YoY Change 138.48% 131.21% -12.89%
TOTAL ASSETS
Total Short-Term Assets $19.93M $26.23M $65.89M
Total Long-Term Assets $11.06M $11.39M $4.928M
Total Assets $30.99M $37.62M $70.81M
YoY Change -49.46% -46.88% -43.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.406M $4.265M $2.656M
YoY Change 98.65% 60.58% -71.46%
Accrued Expenses $4.416M $2.315M $4.086M
YoY Change -10.02% -43.34% -12.6%
Deferred Revenue $1.664M $0.00 $0.00
YoY Change -100.0%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $62.00K
YoY Change
Total Short-Term Liabilities $11.49M $7.597M $7.780M
YoY Change 40.38% -2.35% -62.09%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $202.0K
YoY Change -100.0% -100.0%
Other Long-Term Liabilities $6.200M $6.500M $81.00K
YoY Change 126.44% 7924.69% -99.71%
Total Long-Term Liabilities $6.200M $6.500M $81.00K
YoY Change 112.04% 7924.69%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.49M $7.597M $7.780M
Total Long-Term Liabilities $6.200M $6.500M $81.00K
Total Liabilities $17.70M $14.06M $11.05M
YoY Change 59.38% 27.22% -77.05%
SHAREHOLDERS EQUITY
Retained Earnings -$133.3M -$122.6M -$238.5M
YoY Change -46.14% -48.6% 11.29%
Common Stock $84.00K $84.00K $301.0K
YoY Change -72.09% -72.09% -0.66%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $13.29M $23.56M $59.76M
YoY Change
Total Liabilities & Shareholders Equity $30.99M $37.62M $70.81M
YoY Change -49.46% -46.88% -43.51%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q2
OPERATING ACTIVITIES
Net Income -$10.66M -$7.559M -$9.139M
YoY Change 18.58% -17.29% -46.47%
Depreciation, Depletion And Amortization $0.00 $190.0K $31.00K
YoY Change -100.0% 512.9% 34.78%
Cash From Operating Activities -$5.190M -$9.530M -$9.905M
YoY Change -38.26% -3.79% -5.95%
INVESTING ACTIVITIES
Capital Expenditures $50.00K $20.00K $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $10.03M
YoY Change
Cash From Investing Activities -$40.00K $10.01M $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 60.00K 34.82M -14.00K
YoY Change -452.94% -248814.29% -99.41%
NET CHANGE
Cash From Operating Activities -5.190M -9.530M -9.905M
Cash From Investing Activities -40.00K 10.01M 0.000
Cash From Financing Activities 60.00K 34.82M -14.00K
Net Change In Cash -5.170M 35.30M -9.919M
YoY Change -38.62% -455.88% -24.56%
FREE CASH FLOW
Cash From Operating Activities -$5.190M -$9.530M -$9.905M
Capital Expenditures $50.00K $20.00K $0.00
Free Cash Flow -$5.240M -$9.550M -$9.905M
YoY Change -37.66% -3.58% -3.71%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1720202 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
313148 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
313148 shares
CY2023Q2 angn Warrant Liability Current
WarrantLiabilityCurrent
32000 usd
CY2022Q4 angn Warrant Liability Current
WarrantLiabilityCurrent
0 usd
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6419000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6789000 usd
CY2023Q2 us-gaap Deferred Compensation Sharebased Arrangements Liability Classified Noncurrent
DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent
46000 usd
CY2022Q4 us-gaap Deferred Compensation Sharebased Arrangements Liability Classified Noncurrent
DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent
92000 usd
CY2023Q2 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0 usd
CY2022Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
111060000 usd
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8384723 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
320281 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8370268 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
320281 shares
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
84000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
3000 usd
CY2023Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
14454 shares
CY2022Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
0 shares
CY2023Q2 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
150000 usd
CY2022Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
0 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
146221000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4860000 usd
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-122596000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-107008000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
23557000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-102145000 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
37619000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
22664000 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4944000 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5041000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10428000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9220000 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2833000 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1191000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5154000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2782000 usd
CY2023Q2 us-gaap Costs And Expenses
CostsAndExpenses
7777000 usd
CY2022Q2 us-gaap Costs And Expenses
CostsAndExpenses
6232000 usd
us-gaap Costs And Expenses
CostsAndExpenses
15582000 usd
us-gaap Costs And Expenses
CostsAndExpenses
12002000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-7777000 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6232000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-15582000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-12002000 usd
CY2023Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
23000 usd
CY2022Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
23000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 usd
CY2023Q2 us-gaap Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
321000 usd
CY2022Q2 us-gaap Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
0 usd
us-gaap Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
429000 usd
us-gaap Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
74000 usd
CY2023Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
604000 usd
CY2022Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
604000 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
CY2023Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-9000 usd
CY2022Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
0 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
51000 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1000 usd
CY2023Q2 us-gaap Interest Expense
InterestExpense
714000 usd
CY2022Q2 us-gaap Interest Expense
InterestExpense
1067000 usd
us-gaap Interest Expense
InterestExpense
1056000 usd
us-gaap Interest Expense
InterestExpense
2432000 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
218000 usd
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1067000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2357000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-7299000 usd
us-gaap Net Income Loss
NetIncomeLoss
-15586000 usd
us-gaap Net Income Loss
NetIncomeLoss
-14359000 usd
CY2023Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-2000 usd
CY2022Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
0 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-2000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
0 usd
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7561000 usd
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7299000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15588000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14359000 usd
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.44
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-23.20
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-23.20
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-9.06
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-9.06
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-45.85
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-45.85
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3100957 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3100957 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
314572 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
314572 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1720202 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1720202 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
313148 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
313148 shares
CY2022Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
4997920 shares
CY2022Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
111060000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-102145000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
40000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
34000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
224000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-8029000 usd
CY2023Q1 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
4997920 shares
CY2023Q1 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
111060000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-109876000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
11000 usd
CY2023Q2 angn Temporary Equity Shares Conversion Of Convertible Securities
TemporaryEquitySharesConversionOfConvertibleSecurities
4997920 shares
CY2023Q2 angn Temporary Equity Value Conversion Of Convertible Securities
TemporaryEquityValueConversionOfConvertibleSecurities
111060000 usd
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2400000 usd
CY2023Q2 angn Stock Issued During Period Value Reverse Recapitalization
StockIssuedDuringPeriodValueReverseRecapitalization
19739000 usd
CY2023Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
150000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
279000 usd
CY2023Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-2000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-7559000 usd
CY2023Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
CY2023Q2 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
23557000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-7060000 usd
CY2022Q1 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
1408100 shares
CY2022Q1 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
70439000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-81436000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
3000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3000 usd
CY2022Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
300000 usd
CY2022Q2 angn Temporary Equity Stock Issued During Period Shares New Issues
TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
103637 shares
CY2022Q2 us-gaap Temporary Equity Stock Issued During Period Value New Issues
TemporaryEquityStockIssuedDuringPeriodValueNewIssues
1169000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
113000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-7299000 usd
CY2022Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
1511737 shares
CY2022Q2 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
71608000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-88616000 usd
us-gaap Net Income Loss
NetIncomeLoss
-14359000 usd
us-gaap Depreciation
Depreciation
186000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
283000 usd
angn Interest Expense Noncash
InterestExpenseNoncash
2431000 usd
us-gaap Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
74000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 usd
us-gaap Share Based Compensation
ShareBasedCompensation
270000 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-1000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1083000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
8000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-79000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-251000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
109000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1436000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-337000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17614000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
21000 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
34000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
13000 usd
us-gaap Cash Acquired In Excess Of Payments To Acquire Business
CashAcquiredInExcessOfPaymentsToAcquireBusiness
24001000 usd
us-gaap Payments Of Merger Related Costs Financing Activities
PaymentsOfMergerRelatedCostsFinancingActivities
2366000 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
10000000 usd
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
0 usd
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
1169000 usd
us-gaap Payments For Repurchase Of Equity
PaymentsForRepurchaseOfEquity
150000 usd
us-gaap Payments For Repurchase Of Equity
PaymentsForRepurchaseOfEquity
0 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
67000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
78000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
31552000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1247000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-2000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
13949000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-8829000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8414000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10045000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
22363000 usd
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21682000 usd
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
598000 usd
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
681000 usd
CY2022Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
618000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
22363000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1216000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-1000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-4000 usd
angn Accretion Of Promissory Note Discount From Embedded Derivative
AccretionOfPromissoryNoteDiscountFromEmbeddedDerivative
130000 usd
angn Accretion Of Promissory Note Discount From Embedded Derivative
AccretionOfPromissoryNoteDiscountFromEmbeddedDerivative
0 usd
angn Accretion Of Promissory Note To Face Value
AccretionOfPromissoryNoteToFaceValue
897000 usd
angn Accretion Of Promissory Note To Face Value
AccretionOfPromissoryNoteToFaceValue
0 usd
angn Interest Expense From Promissory Notes Payable
InterestExpenseFromPromissoryNotesPayable
34000 usd
angn Interest Expense From Promissory Notes Payable
InterestExpenseFromPromissoryNotesPayable
0 usd
angn Accretion Of Convertible Notes Discount From Embedded Derivative
AccretionOfConvertibleNotesDiscountFromEmbeddedDerivative
0 usd
angn Accretion Of Convertible Notes Discount From Embedded Derivative
AccretionOfConvertibleNotesDiscountFromEmbeddedDerivative
1639000 usd
angn Accretion Of Convertible Notes Discount From Issuance Costs
AccretionOfConvertibleNotesDiscountFromIssuanceCosts
0 usd
angn Accretion Of Convertible Notes Discount From Issuance Costs
AccretionOfConvertibleNotesDiscountFromIssuanceCosts
219000 usd
angn Interest Expense From Convertible Notes Payable
InterestExpenseFromConvertibleNotesPayable
0 usd
angn Interest Expense From Convertible Notes Payable
InterestExpenseFromConvertibleNotesPayable
574000 usd
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9700000 shares
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-122600000 usd
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21700000 usd
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
0 usd
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3100957 shares
CY2023Q2 angn Recapitalization Exchange Ratio
RecapitalizationExchangeRatio
0.0181
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 operating_segment
us-gaap Use Of Estimates
UseOfEstimates
Use of EstimatesThe Company’s management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could materially differ from those estimates. Significant estimates reflected in these condensed consolidated financial statements include but are not limited to, the accrual of research and development expenses, the valuation of stock-based awards, the operating right of use assets and operating lease liability, and going concern.
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
Concentrations of Credit Risk and Off-Balance Sheet RiskFinancial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash, cash equivalents, and restricted cash. At times, cash balances deposited at major financial banking institutions exceed the federally insured limit. The Company regularly monitors the financial condition of the institutions in which it has depository accounts and believes the risk of loss is minimal. The Company has not experienced any losses in such accounts.
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1935000 usd
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
314572 shares
CY2022Q2 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 usd
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 usd
CY2023Q2 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 usd
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y7M2D
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
586000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
135526 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
10.00
CY2023Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
2700000 usd
CY2022Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.06
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y4M24D
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
314572 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1720202 shares
CY2023Q2 angn Number Of Members Of The Board Of Directors
NumberOfMembersOfTheBoardOfDirectors
9 board_member
CY2023Q2 angn Recapitalization Exchange Ratio
RecapitalizationExchangeRatio
0.0181
CY2023Q2 angn Recapitalization Exchange Ratio
RecapitalizationExchangeRatio
0.0181
CY2023Q2 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
5375751 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8387025 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8387025 shares
CY2023Q2 angn Cash And Cash Equivalents Acquired Through Reverse Recapitalization
CashAndCashEquivalentsAcquiredThroughReverseRecapitalization
24000000 usd
CY2023Q2 angn Other Current Assets Acquired Through Reverse Recapitalization
OtherCurrentAssetsAcquiredThroughReverseRecapitalization
539000 usd
CY2023Q2 angn Promissory Notes Acquired Through Reverse Recapitalization
PromissoryNotesAcquiredThroughReverseRecapitalization
10028000 usd
CY2023Q2 angn Accrued Liabilities Assumed Through Reverse Recapitalization
AccruedLiabilitiesAssumedThroughReverseRecapitalization
2438000 usd
CY2023Q2 angn Net Assets Acquired Through Reverse Recapitalization
NetAssetsAcquiredThroughReverseRecapitalization
32129000 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
600000 usd
CY2023Q2 angn Reverse Recapitalization Transaction Costs
ReverseRecapitalizationTransactionCosts
2900000 usd
angn Reverse Recapitalization Transaction Costs
ReverseRecapitalizationTransactionCosts
2900000 usd
CY2023Q2 angn Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
2278000 usd
CY2022Q4 angn Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
2132000 usd
CY2023Q2 angn Advanced Professional Fees
AdvancedProfessionalFees
241000 usd
CY2022Q4 angn Advanced Professional Fees
AdvancedProfessionalFees
648000 usd
CY2023Q2 us-gaap Prepaid Insurance
PrepaidInsurance
714000 usd
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
104000 usd
CY2023Q2 angn Return Of Collateral For Letter Of Credit
ReturnOfCollateralForLetterOfCredit
618000 usd
CY2022Q4 angn Return Of Collateral For Letter Of Credit
ReturnOfCollateralForLetterOfCredit
0 usd
CY2023Q2 angn Miscellaneous Receivables
MiscellaneousReceivables
557000 usd
CY2022Q4 angn Miscellaneous Receivables
MiscellaneousReceivables
0 usd
CY2023Q2 angn Other Prepaid Expenses And Other Assets Current
OtherPrepaidExpensesAndOtherAssetsCurrent
135000 usd
CY2022Q4 angn Other Prepaid Expenses And Other Assets Current
OtherPrepaidExpensesAndOtherAssetsCurrent
36000 usd
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4543000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2920000 usd
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2141000 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2270000 usd
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1222000 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1123000 usd
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
919000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1147000 usd
CY2022Q4 us-gaap Prepaid Expense Other Noncurrent
PrepaidExpenseOtherNoncurrent
2800000 usd
CY2023Q2 us-gaap Prepaid Expense Other Noncurrent
PrepaidExpenseOtherNoncurrent
2800000 usd
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
709000 usd
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
180000 usd
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1489000 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1491000 usd
CY2023Q2 angn Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
112000 usd
CY2022Q4 angn Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
260000 usd
CY2023Q2 angn Accrued Other Operating Liabilities Current
AccruedOtherOperatingLiabilitiesCurrent
5000 usd
CY2022Q4 angn Accrued Other Operating Liabilities Current
AccruedOtherOperatingLiabilitiesCurrent
4000 usd
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2315000 usd
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q2 angn Recapitalization Exchange Ratio
RecapitalizationExchangeRatio
0.0181
CY2022Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
6948560 shares
CY2022Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
4997920 shares
CY2022Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
4997920 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
854076 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.24
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y8M19D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
135526 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
10.00
angn Share Based Compensation Arrangement By Share Based Payment Award Options Options In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionsInPeriod
351656 shares
angn Share Based Compensation Arrangements By Share Based Payment Award Options Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOptionsOutstandingWeightedAverageExercisePrice
62.04
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
35709 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
6.99
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
20292 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
30.96
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1285257 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
20.62
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y8M4D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3509000 usd
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
558512 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
41.00
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
279000 usd
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
113000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
503000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
270000 usd
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
144814 shares
CY2022Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
53.59
CY2022Q4 angn Class Of Warrant Or Right Weighted Average Life
ClassOfWarrantOrRightWeightedAverageLife
P6Y6M
angn Class Of Warrant Or Right Assumed In Acquisition
ClassOfWarrantOrRightAssumedInAcquisition
3950 shares
angn Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Warrants Assumed In Acquisition
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsWarrantsAssumedInAcquisition
76.00
angn Call Of Warrant Or Right Weighted Average Life Warrants Assumed In Acquisition
CallOfWarrantOrRightWeightedAverageLifeWarrantsAssumedInAcquisition
P5Y2M12D
CY2023Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
148764 shares
CY2023Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
54.19
CY2023Q2 angn Class Of Warrant Or Right Weighted Average Life
ClassOfWarrantOrRightWeightedAverageLife
P6Y6M
CY2023Q2 us-gaap Proceeds From Secured Lines Of Credit
ProceedsFromSecuredLinesOfCredit
700000 usd
CY2023Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
300000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
700000 usd
CY2022Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
300000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
500000 usd
us-gaap Net Income Loss
NetIncomeLoss
-15586000 usd
us-gaap Net Income Loss
NetIncomeLoss
-14359000 usd
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3100957 shares
us-gaap Operating Lease Payments
OperatingLeasePayments
648000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
489000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
8017000 usd
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y10M24D
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.079
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.080
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
751000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1427000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1349000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1383000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1425000 usd
CY2023Q2 angn Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
3232000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
9567000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2163000 usd
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
7404000 usd
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
985000 usd
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6419000 usd
angn Operating Lease Future Minimum Annual Maintenance Payments
OperatingLeaseFutureMinimumAnnualMaintenancePayments
100000 usd
angn Operating Lease Future Minimum Annual Maintenance Payments Due Thereafter
OperatingLeaseFutureMinimumAnnualMaintenancePaymentsDueThereafter
100000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-7559000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-7299000 usd
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.44
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.44
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-23.20
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-23.20
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-9.06
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-9.06
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-45.85
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-45.85
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1434021 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2446547 shares

Files In Submission

Name View Source Status
angn-20230630_cal.xml Edgar Link unprocessable
angn-20230630_pre.xml Edgar Link unprocessable
0001601485-23-000052-index-headers.html Edgar Link pending
0001601485-23-000052-index.html Edgar Link pending
0001601485-23-000052.txt Edgar Link pending
0001601485-23-000052-xbrl.zip Edgar Link pending
angn-20230630.htm Edgar Link pending
angn-20230630.xsd Edgar Link pending
ex311_eltx-06302023x10xq.htm Edgar Link pending
ex312_eltx-06302023x10xq.htm Edgar Link pending
ex321eltx-06302023x10xq.htm Edgar Link pending
ex322_eltx-06302023x10xq.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
angn-20230630_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
angn-20230630_def.xml Edgar Link unprocessable
angn-20230630_htm.xml Edgar Link completed
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending